NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Start Multiple Choice Practice Test
Start Flash Cards

Practice this question and more.

What is the primary disease-modifying antirheumatic drug (DMARD) for sickle cell disease?

  1. Methotrexate

  2. Leflunomide

  3. Hydroxyurea

  4. Sulfasalazine

The correct answer is: Hydroxyurea

Hydroxyurea is the primary disease-modifying antirheumatic drug (DMARD) for sickle cell disease. This is because it helps to reduce the frequency of pain crises and progression of organ damage caused by sickle cell disease. Methotrexate and sulfasalazine are commonly used as DMARDs for other autoimmune conditions such as rheumatoid arthritis, but they are not effective for treating sickle cell disease. Leflunomide is also used as a DMARD for rheumatoid arthritis, but has not been proven to be effective for sickle cell disease. Therefore, hydroxyurea is the most appropriate DMARD for treating sickle cell disease.

More Questions Like This